Evidence map›Paper›PMID 42568042›Full record

ArticleThoracic cancer2026

A Noncanonical MET Exon 14 Splice-Site Variant in Pulmonary Sarcomatoid Carcinoma With Response to Capmatinib.

Hyung-Joo Oh, Yoo-Duk Choi, Yoon-La Choi, Ha-Young Park, Joon-Young Yoon, Jang-Hyeon Kim, Jung-Hwan Lim, Cheol-Kyu Park, In-Jae Oh, Young-Chul Kim

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hyung-Joo OhDivision of Pulmonology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, South Korea.ORCID https://orcid.org/0000-0002-9420-9096
Yoo-Duk ChoiLung Cancer Center, Chonnam National University Hwasun Hospital, Gwangju, South Korea.
Yoon-La ChoiDepartment of Pathology & Translational Genomics, Samsung Medical Center, Sungkyungwan University School of Medicine, Seoul, South Korea.ORCID https://orcid.org/0000-0002-5788-5140
Ha-Young ParkDivision of Pulmonology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, South Korea.
Joon-Young YoonDivision of Pulmonology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, South Korea.
Jang-Hyeon KimDivision of Pulmonology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, South Korea.
Jung-Hwan LimDivision of Pulmonology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, South Korea.ORCID https://orcid.org/0000-0003-0039-0662
Cheol-Kyu ParkDivision of Pulmonology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, South Korea.ORCID https://orcid.org/0000-0001-8701-0786
In-Jae OhDivision of Pulmonology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, South Korea.ORCID https://orcid.org/0000-0003-4837-1321
Young-Chul KimDivision of Pulmonology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, South Korea.ORCID https://orcid.org/0000-0001-7019-7687

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MET exon 14 skipping is an actionable oncogenic driver in non-small cell lung carcinoma (NSCLC); however, noncanonical splice-region variants are frequently classified as variants of unknown significance (VUS), which may result in missed therapeutic opportunities and highlight limitations in current DNA next-generation sequencing (NGS) reporting criteria. We report a patient with pulmonary sarcomatoid carcinoma harboring a noncanonical MET splice donor-proximal indel (c.3022_3028 + 13delinsA), initially interpreted as a VUS, who achieved a rapid and durable response to capmatinib. Subsequent RNA sequencing and droplet digital PCR (ddPCR) confirmed MET exon 14 skipping, supporting the value of orthogonal transcript-level validation for exon-adjacent variants.

Indexed as

BenzamidesCarcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins c-metRNA Splice SitesTriazinesExonsHumansImidazolesMaleBenzamidescapmatinibImidazolesMET protein, humanProto-Oncogene Proteins c-metRNA Splice SitesTriazinescapmatinibcase reportMETsarcomatoid carcinoma

Identifiers

PMID42568042
PMCPMC13451342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.